Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 15/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.57 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.57 |
| ▸ | CCR2 | P41597 | 1/20 | 0.57 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20224126 | 0.94 | CXCR4 (0.49) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| SCHEMBL12673217 | 0.87 | HRH3 (0.50) | TDP1HRH3 | |
| SCHEMBL14747471 | 0.86 | HRH3 (0.53) | TDP1HRH3 | |
| SCHEMBL26351870 | 0.86 | HRH3 (0.53) | TDP1HRH3 | |
| SCHEMBL22642370 | 0.83 | PARP1 (0.46) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| SCHEMBL20037919 | 0.82 | CXCR4 (0.62) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| SCHEMBL4757141 | 0.80 | PPARD (0.49) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| SCHEMBL20249126 | 0.79 | GRM5 (0.42) | KMT2A | |
| SCHEMBL20038107 | 0.79 | CXCR4 (0.62) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| Hydrochloric Acid SCHEMBL27861921 | 0.79 | CXCR4 (0.49) | CXCR4MEN1CHRM2CHRM1ADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | CXCR4 1021/4885MEN1 2609/4885CHRM2 4833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.